Dyax Signs Deal for HTS Biosystems Drug Discovery Instrument
HTS Biosystems, based in Hopkinton, Mass., said last week that Dyax Corporation has purchased a FlexChip high-throughput screening instrument for drug discovery and development.
This is the second FlexChip Dyax has acquired from HTS, the company said. HTS also said that it will supply, for a limited time, a special discounted price to licensees of Dyax’s antibody, peptide, and protein phage display technology.
The companies presented data from the HTS FlexChip system at last week’s IBC Antibody Engineering Conference in San Diego.
The HTS FlexChip combines surface plasmon resonance technology with chip-based array technology for high-throughput screening of kinetic binding constants of antibodies, peptides, and proteins, HTS said.
Definiens and BioImage Pen High Content-Screening Alliance
Definiens and BioImage will co-market their products for high-content cell-based screening assays, and co-develop applications in this area, the companies said this week.
Terms of the non-exclusive deal call for the companies to co-market Definiens' Cellenger software for automated image analysis and BioImage's Redistribution cell-based pathway screenings assays, which measure protein translocation.
In addition, Definiens, based in Munich, Germany, and BioImage of Copenhagen, Denmark, plan to co-develop specific applications for high-content screening.
Prolysis and Proteom Sign Drug-Discovery Deal
UK-based firms Prolysis and Proteom last week announced a drug discovery agreement to optimize Prolysis’ lead antibiotic programs, the companies said.
Under the terms of the agreement, Cambridge-based Proteom will use ProtoScreen and ProtoBuild, its in silico screening and de novo design technology, to aid Prolysis in designing new classes of antibiotics targeting cell division.
Prolysis’ drug discovery process includes the use of proprietary whole-cell assay technology, as well as protein crystallography and medicinal chemistry from its technology partners, David Rice of the University of Sheffield and German firm Evotec OAI.
Financial terms of the deal were not disclosed.
CeMines Opens New Division in Estonia
CeMines has created a new operating division in Estonia called CeMines International, which will become a wholly owned subsidiary of CeMines, the company said today.
In Estonia, CeMines will “expand [its] research-and-development initiatives, establish a regulatory-affairs presence in the European Union, and accelerate commercialization of new methods and technology,” according to CEO Roger Attick.
“A comprehensive international business strategy is central to long-term competitive advantages,” Attick added. “CeMines will also leverage its presence in Europe to cultivate new research partnerships and distribution channels.”
CeMines, based in Golden, Colo., is developing its molecular fingerprinting technologies for early-stage diagnostics and therapeutics.
Blueprint to Re-develop, Maintain AAAS Signal Transduction Database
The American Association for the Advancement of Science has contracted the Blueprint Initiative-North America to re-develop, maintain, and populate the journal Science’s Signal Transduction Knowledge Environment Connections Maps database, Blueprint said last week in a statement.
Under terms of the agreement, Toronto-based Blueprint will gain a non-exclusive royalty-free worldwide license to the database’s Connections Maps Authority Data Entry System, the portal through which users enter data into STKE Connections Maps systems, Blueprint said.
The STKE is a web portal featuring reviews, protocols, and perspectives on signaling, the company said. The portal also provides to members a “virtual journal” made up of articles from 19 individual print journals, the company added.
Blueprint will add “12 to 15” new pathways and authorities during the curation period, in addition to updating and editing existing entries for clarity and conformity, Blueprint said.